Profitable Medical Supplies and Equipment Company Equity Stake For Sale in London, UK

• Global consumer healthcare company focused on smoking harm reduction through patented, drug-free nicotine and tar reduction technology.
• Core product is a liquid solution applied to cigarette filters that blocks up to 99% of tar and nicotine while allowing adult smokers to maintain their normal smoking ritual.
• Targets adult smokers seeking harm reduction and gradual smoking cessation without prescription drugs or behavioural disruption.
• Operates a scalable contract-manufacturing and distribution-led model with sales channels across OTC retail, pharmacies, government health programmes, and international distribution partnerships.
• Built around proprietary technology with worldwide patents and trademarks protected until 20 years from now, creating long-term defensibility in the smoking cessation sector.
• Regulatory clearances and ingredient approvals secured across major markets, including FDA-approved ingredients in the USA, NHS ethical clearance in the UK, TGA Australia, and approvals across 40+ countries.
• Established international footprint with active or contracted distribution and government programmes across GCC countries, Africa, Australia, New Zealand, China, Japan, Singapore, Malaysia, Indonesia, Greece, and Cyprus.
• Additional platform extensions planned for cigarette filter capsules, government smoking-reduction tenders, and solutions designed for the global hookah and shisha market.
• Positioned to address the growing global smoking cessation and harm-reduction market estimated at over $25 billion, serving approximately 1.1 billion smokers worldwide.
• Reports strong financial performance with EBITDA margins of approximately 40%, fully audited financial statements, and no bank borrowings.
• Asset-light operating structure enables rapid scalability while maintaining strong profitability and international expansion flexibility.
• Management has developed a long-term intellectual property monetisation strategy with an indicative IP valuation target of approximately $50 million in the next 6 years.
• Business holds multiple international regulatory clearances, proprietary intellectual property protections, and audited financial compliance across key operating markets.